| Hemophilia A
Eloctate vs Hympavzi
Side-by-side clinical, coverage, and cost comparison for hemophilia a.Deep comparison between: Eloctate vs Hympavzi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHympavzi has a higher rate of injection site reactions vs Eloctate based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Hympavzi but not Eloctate, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Eloctate
Hympavzi
At A Glance
IV infusion
Every 3-5 days
Recombinant Factor VIII Fc fusion protein
SC injection
Weekly
TFPI antagonist
Indications
- Hemophilia A
- Hemophilia A
- Hemophilia B
Dosing
Hemophilia A - Routine Prophylaxis 50 IU/kg IV every 4 days; adjust to 25-65 IU/kg at 3-5 day intervals based on patient response.
Hemophilia A - On-demand (Minor/Moderate Bleeding) 20-30 IU/kg IV, repeat every 24-48 hours until the bleeding episode is resolved.
Hemophilia A - On-demand (Major/Life-threatening Bleeding) 40-50 IU/kg IV, repeat every 12-24 hours until bleeding is resolved (approximately 7-10 days).
Hemophilia A - Perioperative (Minor Surgery) 25-40 IU/kg IV, repeat every 24 hours for at least 1 day until healing is achieved.
Hemophilia A - Perioperative (Major Surgery) 40-60 IU/kg IV preoperatively, then 40-50 IU/kg every 8-24 hours, continuing every 24 hours for at least 7 days post-wound healing.
Hemophilia A, Hemophilia B Loading dose 300 mg SC (two 150 mg injections); maintenance 150 mg SC once weekly starting one week after loading dose; consider dose adjustment to 300 mg SC weekly in patients >=50 kg with inadequate bleeding control.
Contraindications
- Life-threatening hypersensitivity reaction to ELOCTATE or its excipients (sucrose, sodium chloride, L-histidine, calcium chloride, polysorbate 20)
—
Adverse Reactions
Most common in previously treated patients (>0.5%) Arthralgia, malaise, myalgia, headache, rash
Most common in previously untreated patients (>=1.0%) Factor VIII inhibition, device-related thrombosis, rash papular
Postmarketing Factor VIII inhibitor development, hypersensitivity
Most common (>=3%) Injection site reaction, headache, pruritus
Serious Thromboembolic events, hypersensitivity, peripheral swelling, venous thrombosis
Pharmacology
ELOCTATE is a recombinant fusion protein that temporarily replaces missing Coagulation Factor VIII needed for effective hemostasis; its Fc region of IgG1 binds to the neonatal Fc receptor (FcRn), delaying lysosomal degradation and prolonging plasma half-life compared to standard recombinant Factor VIII.
Marstacimab-hncq is a human monoclonal IgG1 antibody that targets the Kunitz domain 2 (K2) of tissue factor pathway inhibitor (TFPI), neutralizing TFPI activity and enhancing thrombin generation via the extrinsic coagulation pathway.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Eloctate
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Hympavzi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Eloctate
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Hympavzi
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (3/8)
Humana
Eloctate
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Hympavzi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EloctateView full Eloctate profile
HympavziView full Hympavzi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.